In this episode of the podcast Rob is solo as he interviews Dr. Anath
Shalev, a diabetes researcher turned founder of startup Tiximed. Dr. Shalev
discusses the discovery of TixnIP, a protein involved in oxidative stress
in beta cells, and its potential for treating diabetes. The conversation
covers the development of TIX 100, an oral medication targeting TixnIP, its
implications for type 1 and type 2 diabetes, and the differences from
existing diabetes treatments like SGLT2 inhibitors and GLP-1 agonists.
Topics discussed:
* Dr. Anas Shalev's background in diabetes research and founding of
Tiximed
* Discovery of TixnIP and its role in beta cell health
* Potential of TIX 100 as a novel oral medication for diabetes
treatment
* Comparison of TIX 100 with existing diabetes treatments like SGLT2
inhibitors and GLP-1 agonists
* Research process behind TixnIP inhibition and development of TIX 100
* Future of diabetes care, combination therapies, and impact on
patients' lives
* Information about Tiximed, clinical trials, and ways to support the
research
00:18 Revolutionizing Diabetes Treatment: From Researcher to Founder
03:47 Revolutionizing Diabetes Treatment: Targeting Beta Cells and
Glucagon Levels
13:47 Revolutionizing Diabetes Treatment: Targeting Beta Cells in
Type 1 and Type 2 Diabetes
17:35 Revolutionizing Diabetes Treatment with Ticks 100: A
Breakthrough in Addressing the Root Cause of the Disease
27:35 The Limitations and Advantages of Verapamil in Diabetes Care
29:47 Advancements in Diabetes Technology and Research: A Look into
the Future
33:04 Exploring Diabetes Treatment Innovations with Dr. Shalev